Left ventricular hypertrophy is a leading risk factor for cardiovascular morbidity and mortality.
Although reverse ventricular remodelling was long thought to be irreversible, evidence from …

It is now becoming apparent that dynamic changes occur within the interstitium that directly
contribute to adverse myocardial remodeling following myocardial infarction (MI), with …

Phenotypic plasticity, or adaptability, of a cell determines its ability to survive and function
within changing cellular environments. Changes in the mechanical environment, ranging …

Methods Male FVB/N mice underwent transverse aortic constriction (TAC) for 5 weeks to
allow for establishment of LVH, followed by treatment with the mTOR inhibitor, Rapamune (2 …

Left ventricular hypertrophy (LVH), a risk factor for cardiovascular morbidity and mortality, is
commonly caused by essential hypertension. Three geometric patterns of LVH can be …

Background—Although resveratrol has multiple beneficial cardiovascular effects, whether
resveratrol can be used for the treatment and management of heart failure (HF) remains …

G-protein coupled receptor (GPCR) mediated activation of the MAPK signalling cascade is a
key pathway in the induction of hypertrophic remodelling of the heart–a response to …

Pathological cardiac hypertrophy is a key risk factor for heart failure. It is associated with
increased interstitial fibrosis, cell death and cardiac dysfunction. The progression of …

SUMMARY 1 Ketamine and xylazine (KX) mixture is the most commonly used anaesthetic
drug during echocardiography in mice to induce sedation and immobility. Nevertheless, the …

Transition from compensated left ventricular (LV) hypertrophy to decompensated heart
failure was characterized using a pressure‐overload induced model to elucidate the …